How to read this page: this is a
company presentation — the speaker owns the outcome he is describing, so the useful extraction is not his conclusion but the
structure of his argument, which can be re-applied and independently checked. Each insight is a method: the calculation or question, how it played out here, and the signal to watch when re-running it. Timestamps deep-link into the video. Its companion is the
same-day Red Chip readout, which covers the same company from the investor side of the table.
9:55 1. Supply-shock math — share of global supply offline × substitutability
The repeatable method
- Start with the concentration map: what share of world production comes from each source country? A commodity where the top two producers are ~50% of supply is a candidate; one with twenty suppliers is not.
- Mark each concentrated source with its current status — producing, impaired, or embargoed — and add up the share that cannot reach a buyer today, for any reason. Physical damage and export controls count the same in the arithmetic.
- Ask the substitutability question: can the buyer use something else, use less, or wait? Where the answer to all three is no, the shortfall converts to price rather than to demand destruction. Helium fails all three — it is inert, has no chemical analogue at cryogenic temperatures, and cannot be manufactured.
- Check regional balance rather than the global total. A globally balanced market with a structurally short region still produces a price event in that region, because the deficit has to be shipped in.
- Distinguish duration: outages measured in months get absorbed by inventory; outages measured in years re-rate contracts. Ask specifically whether damaged facilities are being repaired or written down.
- Cross-check the conclusion against buyer behaviour, not producer rhetoric. Buyers worrying about volume rather than price is the tell that the shortage is real and that price has further to run.
Here: Qatar ~1/3 of world helium + Russia ~15% → Qatar's gas processing damaged by Iran with the strait closed and "some of those facilities impaired for a number of years rather than months," Russia under export controls → "almost 50% of the world's helium supply is currently not available for customers" → the "fifth helium supply crisis." Confirmed on the demand side by Asian semiconductor buyers who are "not so much about price, more concerned about the quantity" (
10:47). The longer-run backdrop is the same shape: the US strategic reserve went from a third of global supply to almost zero and price went $200 → $400–500/mcf (
8:21).
Watch for
- Qatari LNG/helium restart announcements — and, more usefully, whether the restart is described as repair or as replacement capacity.
- Any formalisation or relaxation of the Russian export controls.
- Semiconductor fabs disclosing gas-supply constraints in their own filings — buyer-side confirmation beats producer-side claims.
6:31 2. The grade screen — concentration, not field size, decides who is economic
The repeatable method
- For any by-product commodity (helium in gas, gold in copper, lithium in brine), get the concentration in the host stream and compare it directly with the industry-standard grade.
- Convert the ratio into a processing-cost statement: a producer at 7× the normal grade moves one-seventh the host volume for the same product, so its unit cost is structurally lower regardless of scale.
- Only then look at reserve size. Grade determines whether the project works at all; size determines how long it works for. A high-grade small field beats a low-grade large one.
- Ask what fraction of the resource the current build actually consumes. If phases one and two use a small share of proven acreage, the expansion optionality is real rather than promotional.
- Look for a third-party stamp that the concentration is what management says — a government strategic-asset designation, a certified reserve report, or a development-finance lender's diligence.
Here: Renergen's gas runs
3% helium against ~0.4% in typical US natural gas and ~0.04% in Qatar — roughly 7× and 75×. 1P reserves are "about the same size as what the US federal helium reserve is," while Phase 1 + Phase 2 combined use "about half the yellow box in the middle" of the proven polygon (
13:24). The external stamp: designated a strategic asset by both the South African and United States governments, which is what put US DFC money in the capital stack.
Watch for
- The reserve analysis on the outer acreage promised for later this year — the event that converts "plenty of acreage" into a certified number.
- Any drop in produced helium concentration as more wells are tied in; grade is an average, and averages move.
15:13 3. The operating-leverage-to-price table — build it before you believe the pitch
The repeatable method
- Take the plant's fixed nameplate volume (here 70 mcf/d helium, 2,500 GJ/d LNG) — this is engineering, not forecasting, so treat it as the one hard input.
- Take the base-case revenue and gross profit management gives at a stated price. The difference between them is your implied cash cost, which is largely fixed once the plant is running.
- Re-run gross profit at every price scenario, holding cost constant. Because volume and cost are both fixed, the whole price delta lands in profit — so a 40% price rise can be a 60%+ profit rise.
- Tier the price inputs by evidence quality and never blend them: contracted (signed, bankable), in negotiation (management's claim, unverifiable), reported spot (hearsay, and not the price they will realise on long-term contracts anyway).
- Apply the same table to the expansion phase to see whether the base-case return is a function of the asset or of the price assumption.
- Then reverse it: at what price does gross profit go to zero? A high-leverage asset cuts both ways, and the downside case is the one management will not present.
Here: Phase 1 at $600/mcf + $13–14/GJ → ~$27m revenue, ~$11m gross profit → implied cash cost ~$16m. At the $800–1,000 being negotiated, the
same plant does
$15–20m of gross profit — a ~40–65% price move producing a ~35–80% profit move. Spot is "north of $2,000 I'm told by industry participants" — third tier, hearsay. Phase 2 runs the same table at 13× scale: 900 mcf/d + 34,000 GJ/d → ~$370m revenue and ~$300m gross profit at the
conservative $600 (
15:47), i.e. the expansion case does not need the higher price to work.
Watch for
- The realised price in the first reported quarter of sales versus the $600 base case — the single number that validates or kills the whole table.
- Any gross-profit disclosure that implies cash costs above the ~$16m the base case implies.
25:52 4. Contract tenor and take-or-pay as a financeability signal
The repeatable method
- Ask for the contracted percentage of each product line separately, and the tenor in years. "We have customers" is not an answer; "100% of LNG on 5–15 year contracts" is.
- Check for an escalation mechanism. A fixed-price fifteen-year contract in an inflationary jurisdiction is a liability; an inflation-linked one is an annuity.
- Distinguish the contract types, because they carry different risks: take-or-pay (buyer pays whether or not they lift — revenue certainty), tolling (you are paid a conversion fee on someone else's feedstock — no commodity price risk at all), and spot (full exposure both ways).
- Read the uncontracted slice as a deliberate position, not a gap. Leaving 25–50% of a product on spot in a shortage is a bet; leaving 0% is a financing decision.
- Now connect it to the debt: lenders underwrite the contracted book, not the production forecast. When a facility's drawdown conditions include a contracting threshold, the contracting schedule is the funding schedule.
Here: helium and LNG on
5–15 year contracts indexed to South African PPI;
100% of LNG contracted,
50–75% of helium contracted with the balance sold spot into the shortage. Carbon-14 is a
multi-year take-or-pay tolling agreement with the Canadian customer who is also the feedstock supplier — conversion fee, no commodity risk. Ytterbium and Si-28 are deliberately left on spot/short-term. The link to funding is explicit in the
same-day Red Chip readout: the
$500m DFC + $250m Standard Bank package releases only on Phase 1 nameplate
and 50% of Stage 2 contracted.
Watch for
- Stage 2 contracting crossing the 50% threshold — the checkable trigger on $750m of debt.
- Whether new helium contracts are struck at $600 or nearer the $800–1,000 claimed, and whether tenor shortens as prices rise (a producer shortening tenor is telling you it expects higher prices).
23:04 5. Root-cause triage of a commissioning delay — bought-in component vs process physics
The repeatable method
- When a plant is late, refuse the schedule answer and ask for the failure mode: which specific piece of equipment, from which supplier, failing which specification.
- Sort the answer into one of three buckets, which carry completely different risk:
- Bought-in component (a defective part from a vendor) — bounded, fixable, repeatable failure across units but a known remedy.
- Integration / commissioning — the parts work, the system does not; usually months, sometimes a redesign.
- Process physics — the method does not achieve the claimed result; potentially terminal.
- Demand the evidence that discriminates between them. The decisive question is whether the already-repaired portion of the plant performs to spec. If it does, the physics is proven and the remainder is logistics.
- Check whether the fix is serialised — how many units, at what rate, in what facility. A rework performed by hand in a clean room is a throughput problem with a countable end.
- Ask what changes on the next build: a different supplier, a re-specified part, or incoming inspection. A delay with no process change is a delay that recurs.
- Separately, ask whether the shortfall is capacity or quality. "Running at nameplate" for a partial plant is not the same claim as "producing saleable product."
Here: the Si-28 delay root-causes to
over 400 compressors from a Swiss manufacturer that "failed to meet the specifications set" — the compressors must be hermetically sealed to reach 99.9999% chemical purity, and "the O-rings the compressor manufacturer put into the compressors are faulty." The discriminating evidence Mann offers is exactly the right one: the rebuilt 48 stages "successfully enriching exactly as you'd expect it to enrich… we just need additional compressors to make the cascade longer." The rework is serialised — each compressor stripped, re-sealed, passivated in a clean room. And the capacity-vs-quality distinction is stated plainly at
30:06: "we're at nameplate capacity for the 48 stages… we really need to get to 96 to 100 stages before we can really start producing large quantities."
Watch for
- Stage count disclosed at each update (48 → 96/100) — a hard, countable progress metric rather than a narrative one.
- Whether the second plant (Iceland, "about 12 months from starting construction," 29:06) uses the same compressor supplier.
- The first shipped and invoiced Si-28, not the first enriched Si-28.
26:58 6. Derived-demand chaining — price an upstream input off the downstream product
The repeatable method
- Identify the end product that consumes the input and get its revenue today plus its consensus growth. That is your demand curve, already forecast by people with better information.
- Establish the conversion ratio — is one unit of end-product demand one unit of input demand, or is it diluted by yield, recycling, thrifting or substitution?
- Look for physical constraints that block stockpiling. A short half-life, a perishable form or a boil-off rate means demand must be met continuously and cannot be smoothed by inventory — which converts a supply gap directly into a shortage.
- Count the pipeline behind the lead product to gauge whether today's demand is the peak or the base.
- Map the supply side to its concentration (method 1) and see whether one jurisdiction controls it.
- Look for third-party distress that corroborates the shortage independently of the seller — a customer publicly blaming the input for its own delays is worth more than any producer claim.
Here: NVS' Pluvicto at $3–4bn/yr → consensus $6–8bn by 2030; its active isotope lutetium-177 has a half-life of days, "so you have to manufacture it every week" — no stockpiling — making Yb-176 demand "probably a one-to-one relationship" with drug demand. Pipeline: ~100 radiotherapeutics in phase 1–3. Supply: "Russia is the only country that can enrich ytterbium-176 today in commercial quantities." Independent corroboration:
BMY and
LLY "recently announced delays to their phase three trials because of the isotope supply chain" (
28:14). Against all that, ASPI's answer is ~1 kg/yr.
Watch for
- Pluvicto quarterly revenue and label expansions into further cancer indications — the direct read-through to Yb-176 volume.
- Any second non-Russian commercial Yb-176 enricher appearing; that is what ends the scarcity premium.
- The continuous processing vessel completing (September) and the first commercial Yb-176 shipment.
13:48 7. Treat logistics as a line in the cost of goods, not a footnote
The repeatable method
- For any product that degrades in transit — boil-off, spoilage, decay, moisture — get the loss rate per unit time and multiply by realistic voyage length. That is a direct, unavoidable cost of goods.
- Compare producers on delivered economics rather than at the plant gate. A location advantage of a few shipping days can be worth more than a few dollars of operating cost.
- Check what the customer actually receives, since the degraded form is usually worth far less: liquid versus boiled-off gas, fresh versus decayed isotope.
- Ask whether the advantage is structural (geography, which competitors cannot copy) or contractual (freight rates, which they can).
Here: "about 1% evaporates or turns off into a gas every day you're shipping it. So shipping distances matter. Cape of Good Hope is a great place to ship to all four corners of the world… when customers receive their helium in liquid form, there should be more liquid versus gas and they want the liquid and they don't really want the gas." That is a permanent geographic edge, and the same physics is why lutetium-177's few-day half-life forces weekly manufacture (method 6) — the two are the same constraint in different products.
Watch for
- Whether customers pay a delivered premium for the higher liquid fraction, or simply pocket it — the difference between a margin advantage and a marketing point.
- Freight and ISO-container availability for liquid helium; a boil-off advantage evaporates with a delayed vessel.
5:09 8. Turn the pitch into a dated scorecard — six months, item by item
The repeatable method
- Extract every dated, falsifiable commitment management makes and write it down with its date. Discard everything undated ("growing rapidly," "great runway") — it cannot be scored.
- For each item, decide in advance what evidence would count as met — first invoiced shipment, a filed document, a signed contract — not a press release describing progress.
- Rank the items by informational value. Any milestone that converts a capital project into revenue tells you more than five that do not.
- Score the list at the deadline and use the hit rate itself as your prior for the next set of guidance. A management team's calibration is a measurable, reusable input.
- Track the dependency chains, so a slip early in a chain is recognised as a slip in everything behind it.
Here, the H2-2026 scorecard as given: first Si-28 shipment in H2 (gated on 96–100 stages of re-sealed compressors); C-14 commercial production in H2 (gated on feedstock supply — the plant is currently producing C-12); Yb-176 continuous processing vessel built in
September, commercial production later in the year;
Renergen first helium/LNG shipments in
September, nameplate by
end Q4 once the final wells are tied in through October; Phase 2 construction starting in H2; AlphaNostics candidates into humans "later this year";
QLE spun out "between now and the end of the year" (and, per the
Red Chip readout, not before 13 September). Longer-dated anchors to score much later: Phase 2 first production 2030, and
$300m of group EBITDA in 2031 (
19:38).
Watch for
- September as the concentration point — three separate "firsts" (helium shipment, Yb-176 vessel, and the earliest possible QLE date) land in the same month.
- The distinction between "producing" and "shipped and paid for" in every update; the second is the only one that scores.
19:38 9. Read a management guide by its internal redundancy, not its headline
The repeatable method
- When a long-dated target is given, insist on the division-by-division build-up. A single group number is unfalsifiable; a decomposition can be attacked piece by piece.
- Check the width of each range — management's own uncertainty, stated. Narrow ranges sit on contracted or visible revenue; wide ones sit on hope.
- Sum the low ends and the high ends. If the low-end sum already exceeds the headline, the target is sandbagged; if only the high-end sum reaches it, everything must go right.
- Look for redundancy: does any single division reach the group target on its own? Redundancy is what makes a plan robust to one division failing.
- Set the whole thing against a near-term checkpoint from the same management (method 8) so the far-dated number inherits a measured credibility.
Here: the $300m 2031 EBITDA target decomposes to electronic gases $150–300m, LNG/natural gas $100–200m, medical isotopes $40–100m ("much harder to predict" — the widest relative range, and flagged as such) and radiopharmaceuticals $40–100m ("more visibility over that"). Low-end sum $330m, high-end $700m — so the headline sits below the sum of the low ends. The redundancy is stated outright: "LNG and helium alone, we think can probably do 300 at the current kind of prices." Balanced against that, the same management has already missed on Si-28 timing, which is the calibration input to apply to all of it.
Watch for
- Any revision to the division ranges — the first place a 2031 target erodes is in one segment's low end, long before the headline changes.
- Whether the "helium and LNG alone can do $300m" claim survives contact with the first year of actual realised helium pricing.
Methods distilled from a public YouTube presentation at the Emerging Growth Conference, shared into the Uranium Discord #general channel. The speaker is ASP Isotopes' own CEO — the claims are management's, the tests are the reader's. Not investment advice.